ライフサイエンスコーパス: washout period

1 ose interval and a final dose after a 2-week washout period).

2 3-month treatment period and after a 1-month washout period.

3 These effects persisted after a 6-week washout period.

4 were monitored throughout the treatment and washout period.

5 h to the other study AI after a 2- to 8-week washout period.

6 dine (IdU) for 30 days, followed by a 40-day washout period.

7 e daily or placebo for 6 weeks with a 2-week washout period.

8 ntal Mg/d) or a placebo for 4 wk with a 1-mo washout period.

9 g two 16-wk diet periods separated by a 4-wk washout period.

10 8-d dietary periods were separated by a 28-d washout period.

11 Response returned to baseline within a 2-min washout period.

12 turned for a final visit after a 4-week drug washout period.

13 at the second baseline visit after a 2-week washout period.

14 aseline, after supplementation, and during a washout period.

15 73), or placebo (n=71), followed by a 4 week washout period.

16 y rigorous daily toothbrushing over a 4-week washout period.

17 The trials were separated by a 2-wk washout period.

18 treatment period with a minimum of an 8-week washout period.

19 tient underwent 2 ETTs separated by a 1-week washout period.

20 omized 5-week crossover design with a 5-week washout period.

21 ominent eosinophilic inflammation during the washout period.

22 eatment lasted 7 d and was followed by a 7-d washout period.

23 by the alternative dosage form after a 72-hr washout period.

24 olic acid and placebo separated by an 8-week washout period.

25 (n = 5 in each group), followed by an 8-week washout period.

26 fedipine treatment was retained during a 4 d washout period.

27 irectly observed therapy period and a 4-week washout period.

28 ch, in a random order, separated by a 4-week washout period.

29 -min constant infusion followed by a 110-min washout period.

30 ek treatment period, separated by a two-week washout period.

31 sion period and during a 45-minute adenosine washout period.

32 ion, which was separated from the first by a washout period.

33 pentylxanthine, abolished the PAE during the washout period.

34 thin 6% of baseline in both groups after the washout period.

35 at weeks 4, 8, and 12; and at the end of the washout period.

36 onometry before and after a protocol-defined washout period.

37 to receive the other regimen after a 1-week washout period.

38 function in the montelukast group after the washout period.

39 ame dosage as their prestudy regimen with no washout period.

40 d with iohexol, after 3 years plus a 2-month washout period.

41 y a 3-d placebo, and was separated by a 12-d washout period.

42 gle-site, randomized crossover trial with no washout period.

43 placebo for 30 weeks, followed by an 8-week washout period.

44 elation treatment was permitted with a 7-day washout period.

45 fined treatment weeks, separated by a 4-week washout period.

46 nd isovolumic placebo, separated by a 2-week washout period.

47 Chemotherapy initiation after a 1-year washout period.

48 e order effects, especially when they lack a washout period.

49 et was consumed for 4 wk with a minimum 2-wk washout period.

50 an assisted by AI diagnosis), with a 1-month washout period.

51 d without DL model assistance with a 1-month washout period.

52 t a random allocation sequence with a 1-week washout period.

53 environmental cleaning, followed by a 5-week washout period.

54 imens of 4 daily doses separated by a 14-day washout period.

55 ontrol) for 16 weeks, separated by an 8-week washout period.

56 f simvastatin, 80 mg daily, before a 2-month washout period.

57 weeks, or as controls, followed by a 48-week washout period.

58 ption and returned to baseline following the washout period.

59 ver effect was observed following the 2-week washout period.

60 data, and use of antibiotics outside of the washout period.

61 placebo for 12 months, followed by a 2-month washout period.

62 ctive peptides/d (HSP+), separated by a 2-wk washout period.

63 0 E% fat) for 4 mo each, separated by a 2-wk washout period.

64 ebo or PF-04958242 for 5 days separated by a washout period.

65 intervention periods separated by an 8-week washout period.

66 daily) in random order separated by a 2 week washout period.

67 ir regular medication, followed by a 12-week washout period.

68 from rice and seafood following a three-day washout period.

69 as followed by a 6-week single-blind placebo washout period.

70 ne if changes were sustained during a 4-week washout period.

71 he 2 assessments were separated by a 6-month washout period.

72 ly consumed for 2 wk and separated by a 4-wk washout period.

73 that were separated by a 14-d habitual diet washout period.

74 switched to the other TNF inhibitor with no washout period.

75 r US diet for 24 d each, separated by a 28-d washout period.

76 ) twice daily for 6 months after a screening washout period.

77 ven sequentially for 50 d followed by a 50-d washout period.

78 ssed over to another treatment after an 8-wk washout period.

79 rage (CB) for 8 wk each, separated by a 4-wk washout period.

80 treatment period was separated by a 3-4 week washout period.

81 intervention phases were separated by a 14-d washout period.

82 440 microg of FP daily, separated by 2-week washout periods.

83 Treatment periods were separated by 6-wk washout periods.

84 completed 2 6-d diet phases separated by 6-d washout periods.

85 d) or control in Trial 2 (n = 25), with 4-wk washout periods.

86 -DASH diet) for 3 wk each, separated by 2-wk washout periods.

87 ree 10-week treatment periods and two 6-week washout periods.

88 -wk duration were provided separated by 2-wk washout periods.

89 periods was randomized with at least 2-week washout periods.

90 ll 5 doses with each dose separated by >2-wk washout periods.

91 Challenges were separated by 28-day washout periods.

92 bilastine daily each for 7 days with 14-day washout periods.

93 terbalanced conditions separated by a 2-week washout period: (1) daytime (intake limited to 0800 h-19

94 After a washout period, 12 of the subjects entered a randomized,

95 s, and 12 months and after a further 2-month washout period (14 months).

96 3-wk run-in periods and separated by a 5-wk washout period, 20 healthy subjects (7 men and 13 women)

97 golimod treatment may happen even with short washout periods (4 weeks) and may perpetuate despite ste

98 n (1.5-2 MBq/liter) for 8 min, followed by a washout period (50 min).

99 od [IP]) or sequence 1-0 (6-month IP/3-month washout period/6-month CP).

100 od [IP]) or sequence 1-0 (6-month IP/3-month washout period/6-month CP).

101 nce 0-1 (6-month control period [CP]/3-month washout period/6-month intervention period [IP]) or sequ

102 nce 0-1 (6-month control period [CP]/3-month washout period/6-month intervention period [IP]) or sequ

103 Following a washout period, 99 eligible subjects were randomly assig

104 After a 24-hr washout period, a single oral dose of ketoconazole (400

105 itching to the other TNF inhibitor without a washout period after insufficient primary response to th

106 witching to a second TNF inhibitor without a washout period after primary failure to a first TNF inhi

107 pproach for 18 months, followed by a 6-month washout period, after which the opposite approach was us

108 tonin or placebo daily for 30 days, one-week washout period, all assessments were repeated after each

109 After a washout period, all of the subjects received a one-time

110 After a washout period, all of the subjects received red wine, t

111 After a medication washout period, all patients received intravenous epopro

112 After a washout period, all subjects received RW (30 g alcohol/d

113 y assigned in a crossover trial, and after a washout period, all subjects received RW, dealcoholized

114 essant benefit of treatment after the 4-week washout period, although somatic complaints increased in

115 control cereals for 6 wk, followed by a 6-wk washout period and a 6-wk crossover treatment period.

116 f raltegravir 400 mg on day 10 followed by a washout period and a single dose of raltegravir 400 mg o

117 BP) concentrations were determined after the washout period and after each of the treatments, and cha

118 Additional studies on the impact of the washout period and bendamustine dose were performed.

119 ons were noted to persist following a 3-week washout period and corresponding restoration of circadia

120 ntly activated Notch followed by a prolonged washout period and observed that, in addition to decreas

121 s were crossed over to the other arm after a washout period and repeat baseline symptom assessment.

122 the first intervention, followed by a 3 day washout period and then 5 days with the other interventi

123 bo for three months, followed by a one-month washout period and then by three months of therapy with

124 cing first for 4 weeks, followed by a 4-week washout period and then crossover for an additional 4 we

125 or placebo for 4 weeks followed by a 2-week washout period and then crossover to the alternate treat

126 8 weeks, after which they underwent a 2-week washout period and then received the alternative regimen

127 HF (40%) diet or LF (20%) diet followed by a washout period and then the other diet.

128 therapy for 4 weeks, followed by a 2-4 week washout period and then the other intervention for 4 wee

129 to 0.9 mg/d whose symptoms returned during a washout period and who returned for at least the week 20

130 eek oral lead-in phase, followed by a 1 week washout period and, after safety assessment, three intra

131 y placebo for 8 weeks, followed by a 2-week "washout period" and then 8 weeks of the alternative trea

132 a 1), January 1, 2016, to December 31, 2017 (washout period), and January 1, 2018, to December 31, 20

133 After dietary stabilization, a 2- to 12-week washout period, and a 4-week, single-blind, placebo lead

134 2-mg oral dose, followed by a minimum 14-day washout period, and subsequent coadministration of a sin

135 00-mg oral dose, followed by a minimum 8-day washout period, and subsequent coadministration of a sin

136 oric period of 2 weeks, followed by a 6-week washout period, and then again during a hypercaloric 2-w

137 wice daily for 70 days, followed by a 14-day washout period, and then placebo for 70 days, or the stu

138 t exclude patients on the basis of a placebo washout period, and they used the Hamilton Depression Ra

139 odide) remained in the tumors after the 24-h washout period, and this fraction varied between the dif

140 n either an AB or BA sequence with a 10-week washout period at crossover.

141 After the 5-year washout period at entry, a total of 8 907 422 unique ind

142 30 m, 1 day at 2590 m, separated by a 2-week washout period at less than 800 m.

143 irheumatic drugs (DMARDs) for an appropriate washout period (at least 1 month) and who, after the was

144 A 5-day washout period before CABG was recommended for patients

145 n oil; MD + CO) for 30 d, followed by a 60-d washout period before crossing over to the alternate int

146 hed placebo for 2 weeks followed by a 2-week washout period before crossing over to the alternate tre

147 re treated for 2 weeks, followed by a 2-week washout period before exposure to the next dosage level.

148 Animals had a 7-day washout period before measures of hormone concentration

149 The mean washout period before the initiation of fingolimod was 2

150 an 200 muL/h for 48 h, followed by a 5-7-day washout period before the next infusion, with four total

151 This was followed by a 4-wk washout period before volunteers crossed to the alternan

152 erol were assessed after a 2-wk beta-agonist washout period, before administering study medication on

153 LA and 0% GLA] for 4 wk, followed by an 8-wk washout period, before consuming the opposite oil for 4

154 ) to assess any acute effects, followed by a washout period, before self-administering the spray four

155 ents for 10 wk, and then went through a 4-wk washout period, before switching to the other treatment

156 crossover trial (AB-BA) with a 2- to 4-week washout period between 3-month intervention periods.

157 e for each individual, allowing for a 30-day washout period between control and risk intervals).

158 was administered for 3 weeks, with a 4-week washout period between crossover phases.

159 twice weekly, each for 4 weeks with a 1 week washout period between crossover.

160 tment periods lasted 4 months with a 1-month washout period between diets.

161 zed order for a minimum of 3 wk, with a 1-wk washout period between diets.

162 administered in a random order with a 28-day washout period between infusions.

163 RI examinations independently, with a 4-week washout period between interpretations.

164 y, 3 days per week for 1 week, with a 1-week washout period between the 2 treatment weeks.

165 a single-blind crossover design with a 2-wk washout period between treatments.

166 cebo, twice daily for 4 weeks, with a 2-week washout period between treatments.

167 nistered in a crossover fashion with a 7-day washout period between treatments.

168 2 mg isoflavones/d for 17 d each with a 25-d washout period between treatments.

169 ebo twice daily for a month, with a one-week washout period between treatments.

170 orally in a crossover fashion after a 2-week washout period between treatments.

171 /d) or placebo (n = 22) for 8 wk with a 4-wk washout period between trials.

172 night) sleep conditions for 3 d, with a 4-wk washout period between visits.

173 one of four different sequences with 2-week washout periods between medications.

174 seline period and intervening 2-week placebo washout periods between treatments.

175 A 7-day washout-period between trial periods was used.

176 10 and 50 nM) for 30 min, and after a 60-min washout period, concentration-response curves were deter

177 tween January 2004 and December 2014, with a washout period consisting of the 9 months before and aft

178 A as food energy for 4 wk and, after a 10 wk washout period, consumed a 15% PUFA diet for another 4 w

179 ries from total fat) for 28 d with a >/=2-wk washout period.Consumption of the cashew diet resulted i

180 t, low-fiber diet for 10 wk and after a 2-wk washout period crossed over to the other diet.

181 nitive deficits persisted even after a 3-day washout period during the third phase.

182 ent was followed by a two-week, single-blind washout period during which all patients received placeb

183 ed for a 10-week period followed by a 2-week washout period during which patients were bathed with no

184 120 g FFCC (as per group A) but after a 6-wk washout period during which they excluded cheese before

185 nd no such diagnosis codes during a >=1 year washout period) during 2014-19, who met additional requi

186 reatment periods were separated by a 3-month washout period, during which patients received on-demand

187 After a 14-day washout period, each patient then received 776C85 daily

188 2.5 mg/kg MPD was given, followed by a 4-day washout period (ED 15 -18).

189 ys (from ED 9 to ED 14), followed by a 3-day washout period (ED 15 to ED 18).

190 After a 4-week washout period, eligible patients had the option to swit

191 l of benzodiazepine treatment, followed by a washout period, exacerbated memory impairment in AD tran

192 After a 5-day washout period, five patients received 5 mg apixaban twi

193 , Rockville Centre, NY) followed by a 1-week washout period followed by 4 weeks of a placebo lubricat

194 A 4-week washout period followed the 12-week treatment phase.

195 of colchicine, separated by a minimum 14-day washout period, followed by administration of the approv

196 or CD-TREAT for 7 days, followed by a 14-day washout period, followed by the alternate diet.

197 as enhanced in LPS-trained MSCs, 3 d after a washout period following primary stimulation.

198 mild asthmatics and research needs (eg long washout period for inhaled corticosteroids).

199 ir every 2 months, for PrEP (after a 180-day washout period for previous PrEP use).

200 ervention phases were separated by a 6-month washout period for the installation of the system and fo

201 tastatic, unresectable cancers who were in a washout period from chemotherapy.

202 renia (N = 10) and after at least a two-week washout period from standard of care antipsychotics.

203 After a washout period >/= 4 wk, subjects received an intravenou

204 period (at least 1 month) and who, after the washout period, had a stable joint count (at least 10 te

205 After a washout period, hospitals switched to the other fluid fo

206 1 and 4 days of treatment, and after a 6-day washout period, hypothesizing dose-dependent decreases i

207 or men and women, respectively), with a 4-wk washout period in between the diets during which the sub

208 ment in a 3 x 3 crossover design with a 1-wk washout period in between treatments.

209 trigine followed by mexiletine, with a 7-day washout period in between.

210 wo separate experimental days, with a 1-week washout period in between.

211 steroid for 1 to 2 weeks with a 1- to 2-week washout period in between.

212 00 mg BID for 14 days, or vice-versa, with a washout period in between.

213 ds with placebo in random order, with 1-week washout periods in between.

214 records for 12 months prerandomisation, the washout period (interval between randomisation and data

215 randomized Latin square design study with a washout period of >/=14 d was conducted.

216 Each diet was consumed for 4.5 wk, with a washout period of >/=2 wk between diet phases.

217 After the washout period of >/=28 d, the same participants consume

218 A washout period of >=4 weeks followed each dosing panel.

219 s who each completed 5 visits with a minimum washout period of 1 wk between testing days.

220 After a washout period of 1 wk, the protocol was repeated with a

221 After a washout period of 10-15 wk, the subjects were fed the al

222 After a washout period of 12 or more months, dermatopathologists

223 ional treatment for 26 weeks, separated by a washout period of 17 weeks.

224 th acute myocardial infarction followed by a washout period of 2 months before crossing over to 1 yea

225 005% were studied separately, with a minimum washout period of 2 weeks between studies.

226 p) or without (continuous treatment group) a washout period of 20 weeks.

227 and valsartan (160 mg/d) for 7 days, with a washout period of 3 weeks in between the treatments.

228 After a washout period of 3 weeks, subjects were switched to the

229 After a washout period of 4 months, the subjects consumed the sa

230 dextrin placebo 3 times/d (HFr); there was a washout period of 4 to 10 wk between each condition.

231 vely] for 6 wk in a crossover design, with a washout period of 4 wk.

232 ring wash-in period of 20 min, followed by a washout period of 40 min.

233 o cereal bars were consumed for 8 wk, with a washout period of 8 wk between the crossover.

234 of olive oil alone for 24 wk, followed by a washout period of 8 wk, and then the alternative capsule

235 Following a 2-day washout period of adequate sleep, adolescents completed

236 e and an AI-augmented digital system, with a washout period of at least 12 weeks between use of each

237 y protein/d) diets for 1 week, followed by a washout period of at least 2 weeks.

238 or a typical Australian diet, followed by a washout period of at least 21 days, before crossing over

239 This injection was followed by a washout period of at least 3 days.

240 After a washout period of at least 4 weeks, participants were cr

241 reatment periods were separated by an active washout period of at least 9 weeks.

242 r 3 hours daily for 5 months, with a 1-month washout period of no patching before the 6-month primary

243 s were consumed in random order separated by washout periods of > or =2 wk.

244 breast cancer in the nonsurgical group after washout periods of 1 year (hazard ratio [HR], 1.40 [95%

245 rage, 9.2, 22.5, 46.3 and 91 mg . d(-1) with washout periods of 2 wk between each intake.

246 Following an interval (washout period) of 2-3 months at the end of the first ph

247 ions in random sequence: (1) after a 27-hour washout period (Off-BB) and (2) 3 hours after beta-block

248 During a 6-month washout period, ox-LDL levels increased.

249 After a minimum 7-day washout period, participants began taking one 300-mg tab

250 Following a 2-week washout period, participants crossed over to the alterna

251 Following a 4-week washout period, participants crossed over to the other t

252 During the subsequent 6-week washout period, participants implemented only the home e

253 After a 2-week washout period, participants in each group received the

254 After a 2-week washout period, participants received escitalopram titra

255 After a 3-week, single-blind placebo-washout period, participants were randomized to diet and

256 /kg orally every 3 days followed by a 1-week washout period), patients were crossed over to the alter

257 After a 2-10-day drug washout period, patients began treatment with clozapine

258 After a washout period, patients crossed over for an additional

259 After a 1-week washout period, patients crossed over to treatment B (pl

260 After a washout period, patients meeting entry criteria were ran

261 After a 2-day washout period, patients were re-treated with VX-710 on

262 After a washout period, patients were then crossed over to the a

263 After a second washout period, patients were treated with 776C85 daily

264 After a 21-day washout-period (PD70), mice were either euthanized (tiss

265 A 6-wk washout period separated the treatment periods.

266 After a 10- to 21-day washout period, subjects crossed over to either placebo

267 After a 2-week washout period, subjects received the alternate treatmen

268 Medication conditions were separated by a washout period that was 7 days.

269 After a 4-mo washout period the participants switched diet.

270 After a washout period, the hemodynamic effects of this infusion

271 At 14 months, after a 2-month washout period, the mean MDS-UPDRS motor scores in the o

272 After a 60-min washout period, the other mask was applied.

273 Following a washout period, the procedure was repeated with the alte

274 sed nightly for 4 wk (T2) followed by a 1-wk washout period, then 4 wk (T4) using the alternate OA.

275 twice daily for 4 weeks followed by a 4-week washout period, then oral levetiracetam, 125 mg, twice d

276 wice daily, or placebo for 8 weeks, a 2-week washout period, then the alternative therapy for 8 weeks

277 After a 3-7 day-placebo washout period, there was a 4-week, double-blind, fixed-

278 After a washout period, they crossed over to the alternate thera

279 Following a 90-day washout period, they were treated for 90 days with the o

280 2016, start date were excluded as a 6-month washout period to allow time in the evaluation period fo

281 the effect, followed by a randomised 4-week washout period to assess withdrawal effects.

282 nsitized state that requires an agonist-free washout period to recover.

283 carefully selecting treatment durations and washout periods to assess incremental improvement in air

284 n pelvis motion and step width, separated by washout periods to detect the presence of potential afte

285 then participants were crossed over with no washout period, to the other group for use for another 1

286 After a 12 +/- 1 wk washout period, treatments were reversed.

287 Following a minimum 7-day washout period (until the symptoms induced by the previo

288 ants completed two sessions (with a one-week washout period) via Zoom.

289 A 2-week washout period was followed by three 4-week periods of o

290 A 3-week washout period was implemented between the interventions

291 , FTHA infusion was terminated, and a 15-min washout period was observed.

292 rospective paired-reader study with a 4-week washout period was used to evaluate three different AI U

293 Washout periods were 2-4 wk for both groups.

294 During a washout period when the curl field was removed, preparat

295 l syndromes should avoid somatostatin analog washout periods when possible and should include quality

296 ment (primary outcome) and during the 2-week washout period with the use of mixed-effects regression

297 ts undertook the alternate diet after a 2-wk washout period, with results compared after the diet per

298 min, and this step was followed by a 20-min washout period without tracer in the perfusion medium.

299 Changes persisted during a 2 week washout period without weights.

300 ab treatment, duration and management of the washout period (WP), and relapse or adverse events durin